Quarterly ResultMay 13, 2026, 06:31 AM
Veru Inc. Q2 Net Loss $2.7M; PLATEAU Study Interim Analysis Q1 2027
AI Summary
Veru Inc. announced its fiscal 2026 second quarter financial results, reporting a significant reduction in net loss to $2.7 million, or $0.12 per share, compared to $7.9 million, or $0.54 per share, in the prior year's quarter. The company also provided a corporate update, highlighting that the Phase 2b PLATEAU clinical study, evaluating enobosarm + semaglutide for higher quality weight reduction, is actively enrolling and on track for interim analysis in the first quarter of calendar year 2027.
Key Highlights
- Phase 2b PLATEAU clinical study interim analysis expected in Q1 calendar year 2027.
- Q2 2026 net loss decreased to $2.7 million, or $0.12 per share, from $7.9 million, or $0.54 per share in Q2 2025.
- Q2 2026 operating loss decreased to $7.2 million from $8.1 million in Q2 2025.
- Research and development expenses for Q2 2026 decreased to $3.1 million from $3.9 million in Q2 2025.
- General and administrative expenses for Q2 2026 decreased to $4.1 million from $5.2 million in Q2 2025.
- Cash, cash equivalents, and restricted cash were $27.6 million as of March 31, 2026, up from $15.8 million as of September 30, 2025.